The Performance of Psoriatic Arthritis Screening Questionnaires in Patients with Psoriasis.

The Performance of Psoriatic Arthritis Screening Questionnaires in Patients with Psoriasis. J Rheumatol. 2019 Nov 01;: Authors: Haddad A, Feld J, Zisman D Abstract Several screening questionnaires have been developed to identify patients with psoriatic arthritis (PsA) in the psoriasis population in dermatology and general practice settings1,2,3,4,5 However, the diagnosis of PsA using these questionnaires is a topic for debate, partly because of disease heterogeneity, and the complications from inconsistent performance results6,7,8,9. PMID: 31676694 [PubMed - as supplied by publisher]
Source: Journal of Rheumatology - Category: Rheumatology Tags: J Rheumatol Source Type: research

Related Links:

CONCLUSIONS: Our results confirm that CZP can be administered safely and effectively to treat both psoriasis and psoriatic arthritis irrespective of previous treatments with biologic agents. PMID: 33034437 [PubMed - as supplied by publisher]
Source: Giornale Italiano di Dermatologia e Venereologia - Category: Dermatology Tags: G Ital Dermatol Venereol Source Type: research
Conclusion: This large study did not support that a high intake of fibre and/or a low intake of meat had a high impact on the risk of late-onset CID. PMID: 33029091 [PubMed - in process]
Source: International Journal of Medical Sciences - Category: Biomedical Science Tags: Int J Med Sci Source Type: research
CONCLUSIONS: In this review, we include a study of the new anti-IL-17 biological agents (secukinumab, ixekizumab, and bromalizumab ) used for moderate-to-severe psoriasis and psoriatic arthritis treatment in clinical practice, as well as pivotal trials with bimekizumab. We study the relationship of these biological agents and the appearance of candidiasis in its various clinical forms. PMID: 33026212 [PubMed - as supplied by publisher]
Source: Giornale Italiano di Dermatologia e Venereologia - Category: Dermatology Tags: G Ital Dermatol Venereol Source Type: research
Cyclic adenosine monophosphate (cAMP) acts as a second messenger for intercellular signal transduction. In particular, the cAMP-PKA-CREB pathway is crucial for the regulation of inflammatory genes in immune cells. To target that pathway in immune responses, phosphodiesterase 4 (PDE4) inhibitors that inhibit the conversion of cAMP to AMP were developed. [1] Apremilast, a PDE4 inhibitor, was approved for the oral treatment of psoriasis and psoriatic arthritis. Additionally, a modest efficacy of apremilast for atopic dermatitis (AD) has been shown.[2] Crisaborole, another PDE4 inhibitor, was approved for the topical treatment...
Source: Journal of Dermatological Science - Category: Dermatology Authors: Tags: Letter to the Editor Source Type: research
ConclusionOur study can imply that IL ‐17A is a valuable, useful and low‐cost biomarker in detecting early axial SpA changes in asymptomatic and nonradiographic axial SpA (nr‐axial SpA) psoriatic patients that helps early management and prevent progressive axial involvement and disabilities.
Source: International Journal of Rheumatic Diseases - Category: Rheumatology Authors: Tags: ORIGINAL ARTICLE Source Type: research
CONCLUSION: In this US real-world cohort, most patients had multidomain disease presentations, which was associated with worse disease activity, QOL, and work productivity measures. This study highlights the heterogeneity of PsA and the importance of assessing all PsA domains for optimizing disease management. PMID: 33004532 [PubMed - as supplied by publisher]
Source: Journal of Rheumatology - Category: Rheumatology Tags: J Rheumatol Source Type: research
Publication date: Available online 2 October 2020Source: Journal of the Formosan Medical AssociationAuthor(s): Tsen-Fang Tsai, Tsu-Yi Hsieh, Ching-Chi Chi, Chung-Tei Chou, Lin-Fen Hsieh, Hsin-Hua Chen, Rosaline Chung-Yee Hui, Chih-Hung Lee, Chin-Hsiu Liu, Hwa-Chang Liu, Kai-Jieh Yeo, Chun-Hsiung Chen, Hung-An Chen, Ying-Chou Chen, Yi-Ju Chen, Hsien-Yi Chiu, Ji-Chen Ho, Yu-Huei Huang, Po-Ju Lai, Woan-Ruoh Lee
Source: Journal of the Formosan Medical Association - Category: General Medicine Source Type: research
Pregnancy outcomes data are increasingly emerging but dermatologists, rheumatologists, and their female patients with psoriasis and psoriatic arthritis (PsA) want much more.Medscape Medical News
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Ob/Gyn & Women ' s Health News Source Type: news
ology Association (TRA) and the Taiwanese Association for Psoriasis and Skin Immunology (TAPSI) Abstract In Taiwan, the incidence and prevalence of psoriatic arthritis (PsA) have risen significantly in recent years. Moreover, data from the Taiwan National Health Insurance Research Database (NHIRD) show that more than 85% of PsA patients are treated with just non-steroidal anti-inflammatory drugs (NSAIDs) and/or conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). Taiwanese clinicians have also expressed concerns regarding uncertainties in the diagnosis of PsA and the delayed, interrupted, and/...
Source: J Formos Med Assoc - Category: General Medicine Authors: Tags: J Formos Med Assoc Source Type: research
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Glob...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Arthritis | Dermatology | General Practices | Primary Care | Psoriasis | Psoriatic Arthritis | Rheumatology | Skin